Tamoxifen induces permanent growth arrest through selective induction of apoptosis in growth plate chondrocytes in cultured rat metatarsal bones

Bone

Volumn 40, Issue 5, 2007, Pages 1415-1424

  Chagin, Andrei S ^a   Karimian, Elham ^a   Zaman, Farasat ^a   Takigawa, Masaharu ^b   Chrysis, Dionisios ^a   Sävendahl, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Caspases; Chondrocytes; Estrogen; Tamoxifen

Indexed keywords

BROXURIDINE; CASPASE; CASPASE 3; CASPASE 8; CASPASE 8 INHIBITOR; CASPASE 9; CASPASE 9 INHIBITOR; FAS ANTIGEN; FAS LIGAND; TAMOXIFEN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE GROWTH; CARTILAGE CELL; CELL DEATH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; GROWTH PLATE; GROWTH RETARDATION; HUMAN; HUMAN CELL; METATARSAL BONE; NICK END LABELING; NONHUMAN; PROTEIN SECRETION; RAT; TISSUE CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; CHONDROCYTES; FAS LIGAND PROTEIN; GROWTH PLATE; HUMANS; METATARSAL BONES; RATS; TAMOXIFEN;

EID: 34047254530     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.12.066     Document Type: Article

References (41)

1. Bilezikian J.P., Morishima A., Bell J., and Grumbach M.M. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 339 (1998) 599-603
2. Chagin A.S., Chrysis D., Takigawa M., Ritzen E.M., and Savendahl L. Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis. J. Endocrinol. 188 (2006) 193-203
3. Chagin A.S., Chrysis D., Takigawa M., Ritzen E.M., and Savendahl L. Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis. J. Endocrinol. 188 (2006) 193-203
4. Chrysis D., Zaman F., Chagin A.S., Takigawa M., and Savendahl L. Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3′-kinase signaling pathway. Endocrinology 146 (2005) 1391-1397
5. Cummings S.R., Palermo L., Browner W., Marcus R., Wallace R., Pearson J., et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283 (2000) 1318-1321
6. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 (2004) 205-219
7. De Luca F., Barnes K.M., Uyeda J.A., De-Levi S., Abad V., Palese T., et al. Regulation of growth plate chondrogenesis by bone morphogenetic protein-2. Endocrinology 142 (2001) 430-436
8. Derman O., Kanbur N.O., and Kutluk T. Tamoxifen treatment for pubertal gynecomastia. Int. J. Adolesc. Med. Health 15 (2003) 359-363
9. Eugster E.A., Rubin S.D., Reiter E.O., Plourde P., Jou H.C., and Pescovitz O.H. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J. Pediatr. 143 (2003) 60-66
10. Fadeel B., Ahlin A., Henter J.I., Orrenius S., and Hampton M.B. Involvement of caspases in neutrophil apoptosis: regulation by reactive oxygen species. Blood 92 (1998) 4808-4818
11. Ferlini C., Scambia G., Marone M., Distefano M., Gaggini C., Ferrandina G., et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br. J. Cancer 79 (1999) 257-263
12. Fitts J.M., Klein R.M., and Powers C.A. Comparison of tamoxifen and testosterone propionate in male rats: differential prevention of orchidectomy effects on sex organs, bone mass, growth, and the growth hormone-IGF-I axis. J. Androl. 25 (2004) 523-534
13. Fitts J.M., Klein R.M., and Powers C.A. Estrogen and tamoxifen interplay with T(3) in male rats: pharmacologically distinct classes of estrogen responses affecting growth, bone, and lipid metabolism, and their relation to serum GH and IGF-I. Endocrinology 142 (2001) 4223-4235
14. Genazzani A.R., Gadducci A., and Gambacciani M. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. Climacteric 4 (2001) 181-193
15. Goldenberg G.J., and Froese E.K. Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vitro. Cancer Res. 42 (1982) 5147-5151
16. Goldzieher M.A. Treatment of excessive growth in the adolescent female. J. Clin. Endocrinol. Metab. 16 (1956) 249-252
17. Guo B., Zhai D., Cabezas E., Welsh K., Nouraini S., Satterthwait A.C., et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423 (2003) 456-461
18. Kisanga E.R., Gjerde J., Guerrieri-Gonzaga A., Pigatto F., Pesci-Feltri A., Robertson C., et al. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin. Cancer Res. 10 (2004) 2336-2343
19. Kisanga E.R., Gjerde J., Schjott J., Mellgren G., and Lien E.A. Tamoxifen administration and metabolism in nude mice and nude rats. J. Steroid Biochem. Mol. Biol. 84 (2003) 361-367
20. Kreher N.C., Eugster E.A., and Shankar R.R. The use of tamoxifen to improve height potential in short pubertal boys. Pediatrics 116 (2005) 1513-1515
21. Kusec V., Virdi A.S., Prince R., and Triffitt J.T. Localization of estrogen receptor-alpha in human and rabbit skeletal tissues. J. Clin. Endocrinol. Metab. 83 (1998) 2421-2428
22. Lawrence S.E., Faught K.A., Vethamuthu J., and Lawson M.L. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J. Pediatr. 145 (2004) 71-76
23. Li X., Takahashi M., Kushida K., Koyama S., Hoshino H., Kawana K., et al. The effect of tamoxifen on bone metabolism and skeletal growth is different in ovariectomized and intact rats. Calcif. Tissue Int. 59 (1996) 271-276
24. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326 (1992) 852-856
25. Mandlekar S., and Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6 (2001) 469-477
26. Martensson K., Chrysis D., and Savendahl L. Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J. Bone Miner. Res. 19 (2004) 1805-1812
27. McDonnell D.P., and Norris J.D. Connections and regulation of the human estrogen receptor. Science 296 (2002) 1642-1644
28. Moodbidri M.S., and Shirsat N.V. Activated JNK brings about accelerated apoptosis of Bcl-2-overexpressing C6 glioma cells on treatment with tamoxifen. J. Neurochem. 92 (2005) 1-9
29. Morishima A., Grumbach M.M., Simpson E.R., Fisher C., and Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80 (1995) 3689-3698
30. Nilsson L.O., Boman A., Savendahl L., Grigelioniene G., Ohlsson C., Ritzen E.M., et al. Demonstration of estrogen receptor-beta immunoreactivity in human growth plate cartilage. J. Clin. Endocrinol. Metab. 84 (1999) 370-373
31. Nilsson O., Abad V., Chrysis D., Ritzen E.M., Savendahl L., and Baron J. Estrogen receptor-alpha and -beta are expressed throughout postnatal development in the rat and rabbit growth plate. J. Endocrinol. 173 (2002) 407-414
32. Nilsson O., Falk J., Ritzen E.M., Baron J., and Savendahl L. Raloxifene acts as an estrogen agonist on the rabbit growth plate. Endocrinology 144 (2003) 1481-1485
33. Perry M.J., Gujra S., Whitworth T., and Tobias J.H. Tamoxifen stimulates cancellous bone formation in long bones of female mice. Endocrinology 146 (2005) 1060-1065
34. Perry R.R., Kang Y., and Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann. Surg. Oncol. 2 (1995) 238-245
35. Robinson S.P., Langan-Fahey S.M., Johnson D.A., and Jordan V.C. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos. 19 (1991) 36-43
36. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17 (1998) 1675-1687
37. Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331 (1994) 1056-1061
38. Takigawa M., Tajima K., Pan H.O., Enomoto M., Kinoshita A., Suzuki F., et al. Establishment of a clonal human chondrosarcoma cell line with cartilage phenotypes. Cancer Res. 49 (1989) 3996-4002
39. Vandenabeele P., Vanden Berghe T., and Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci. STKE 2006 (2006) pe44
40. Venn A., Bruinsma F., Werther G., Pyett P., Baird D., Jones P., et al. Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 364 (2004) 1513-1518
41. Wu X., Ahn E.Y., McKenna M.A., Yeo H., and McDonald J.M. Fas binding to calmodulin regulates apoptosis in osteoclasts. J. Biol. Chem. 280 (2005) 29964-29970